Sally Church, PhD writes about cancer drug development on Pharma Strategy Blog where she brings science to life.
This week she wrote about the American Association for Cancer Research (AACR) international conference on “Frontiers in Basic Cancer Research” that has been taking place in San Francisco.
Meetings such as these are important because it is through understanding basic biology that the next generation of cancer drugs will evolve. Two presentations on pancreatic cancer stood out at the AACR conference.
Pancreatic cancer is the fourth most common cause of cancer death in the United States and has a poor prognosis – the median overall survival for those with metastatic disease is 6 months!
Sally discusses the research presented in San Francisco by Barbara Gruener that “EGFR plays an “unappreciated’ central role in the carcinogenic process.”
What does this mean for those with pancreatic cancer? Sally’s analysis is that “EGFR therapy might be a logical approach for early pancreatic treatment than is currently undertaken” for those with metastatic disease.
Sally in her insightful blog post also discusses data presented at the conference by Dana Haddad who did work at Memorial Sloan-Kettering Cancer Center (MSKCC) on the potential for treatment of pancreatic cancer with an oncolytic virus (GLV-1h153).